mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Please contact the Account Manager for opportunities with this organisation

Bayer drug Visanne gains marketing approval in Europe

Posted on 09/12/2009 in Pharmaceutical Company Product News

Bayer has revealed that its endometriosis therapy Visanne has been approved for marketing in Europe.

The recommendation for the once-daily oral tablet was made this week following the results of a clinical trial which found that the drug is effective in the relief of endometriosis pain, has been shown to reduce lesions and demonstrates safety and tolerability.

It is indicated for short-term use only, as safety concerns - such as decreased bone mineral density and side effects such as hot flushes - currently limit its prolonged use.

Phil Smits, head of Bayer's women's healthcare business unit, stated: "Patients often need to use different combinations of the available treatment options and even undergo repeat surgical procedures. There is therefore a high medical need for new treatment options."

In related news, Bayer this week announced that 20 mg once-daily doses of its novel oral anticoagulant rivaroxaban yielded positive results during a phase III trial.

Other news stories from 09/12/2009

Read more in the Zenopa News Archive

How this news is generated

Alessia
Account Manager
for this opportunity

01494 818 010
(Mon to Fri 0830 to 1800 hours)
alessia@zenopa.com

Latest News

Bayer establishes new medical devices materials branding

Bayer Schering Pharma granted orphan drug status for CF treatment

Bayer Schering Pharma launches trial of breast cancer treatment

Bayer launches USB-based blood glucose meter

Bayer hails strong 2009 performance

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use